

Special Issue

Mesenchymal Stromal Cell-Derived Secretome for Immunomodulation and Tissue Remodeling

Message from the Guest Editor

Although the regenerative and immunomodulatory effects of mesenchymal stromal cells (MSCs) have been extensively studied as a potential therapy for a wide range of inflammatory and degenerative diseases, they have also been related to poor effectiveness, uncertain biosafety, and challenging regulatory pathways. Moreover, the beneficial effects of MSCs have been mainly attributed to their paracrine secretion, known as secretome. Formed by soluble factors and extracellular vesicles (EVs), the MSC-derived secretome has been proven to elicit immunomodulatory, proliferative, anti-oxidative or angiogenic effects beneficial for inflammation management and tissue repair, thus becoming a new and promising alternative for immune-mediated inflammatory diseases and regenerative medicine. This Special Issue aims to highlight the latest advances in enhancing the therapeutic potential of MSC-derived secretome or its components, including preconditioning strategies, isolation/purification, and delivery systems. We welcome original research and review articles that may contribute to increasing knowledge and discussion on this topic.

Guest Editor

Dr. Edorta Santos-Vizcaino

NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain

Deadline for manuscript submissions

closed (10 January 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/65487

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).